Multi-omics characterization identifies AHCY as a prognostic biomarker driving immunometabolic reprogramming in bladder cancer. Peng Q, Zhang M, Zhao S, Guo Y, et al. Transl Oncol 2025;64:102652.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Peng Q, Zhang M, Zhao S, Guo Y, et al. Multi-omics characterization identifies AHCY as a prognostic biomarker driving immunometabolic reprogramming in bladder cancer. Transl Oncol 2025;64:102652.
PMID: 41411923